ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first shipment of BARYTHRAX inj., the world's first recombinant anthrax vaccine. The product, jointly ...

Pune, India, Sept. 04, 2023 (GLOBE NEWSWIRE) -- The global recombinant DNA technology market is expected to grow during 2023 to 2030. The growth of the market is driven by the increasing demand for ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...

The production of antibodies has thus far been limited to a small number of species, most often murine, which has led to availability and scalability challenges for scientists. Technology Networks ...

The market for Recombinant DNA Technology was valued at US$ 445 billion in 2021 and is anticipated to grow at a CAGR of 7.2% through 2032. Recombinant DNA technology’s introduction has changed how ...

MELBOURNE, Australia--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from ...

Jiangsu Recbio Technology Co Ltd : Li Bu a démissionné de son poste de directeur exécutif Chen Qingqing a démissionné de son ...

THE STRUCTURE AND FUNCTION OF RECOMBINANT HUMANIZED TYPE III COLLAGEN AS WELL AS ITS RELATED PRODUCT approved by CHINA NMPa for COSMETICS USE (ADAPTED FROM THE AUTHORS’ PUBLICATION IN Biochemical and ...